Payment overview · 2025
General Payments
$66.82
3 reported records · 3 companies
Healthcare provider profile · identity verified
Michael A Schreckengost, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HENDERSON, NV · NPI 1831733542
Verified facts
What the public records show
CMS Open Payments records show Michael A Schreckengost, FNP-BC received $66.82 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.53 | 38.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.72 | 32.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.57 | 29.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $66.82 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 94 |
| Lisinopril | Lisinopril | 273 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 74 |
| Losartan Potassium | Losartan Potassium | 237 | 76 |
| Omeprazole | Omeprazole | 159 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 42 |
| Alendronate Sodium | Alendronate Sodium | 125 | 39 |
| Metformin Hcl | Metformin Hcl | 125 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 21 |
| Simvastatin | Simvastatin | 121 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 118 | 19 |
| Tramadol Hcl | Tramadol Hcl | 118 | 24 |
| Ozempic | Semaglutide | 117 | 24 |
| Gabapentin | Gabapentin | 107 | 36 |
| Alprazolam | Alprazolam | 106 | 27 |
| Trazodone Hcl | Trazodone Hcl | 103 | 34 |
| Meloxicam | Meloxicam | 99 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 33 |
| Famotidine | Famotidine | 82 | 30 |
| Mounjaro | Tirzepatide | 82 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 24 |
| Montelukast Sodium | Montelukast Sodium | 72 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 13 |
| Glipizide Er | Glipizide | 68 | 22 |
| Lorazepam | Lorazepam | 67 | 13 |
| Azithromycin | Azithromycin | 64 | 56 |
| Ondansetron Odt | Ondansetron | 63 | 29 |
| Eliquis | Apixaban | 57 | 20 |
| Ibuprofen | Ibuprofen | 57 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 17 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 16 |
| Furosemide | Furosemide | 51 | 20 |
| Carvedilol | Carvedilol | 50 | 16 |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 16 |
| Finasteride | Finasteride | 43 | 17 |
| Atenolol | Atenolol | 42 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 15 |
| Metformin Hcl Er | Metformin Hcl | 38 | 14 |
| Potassium Chloride | Potassium Chloride | 37 | 14 |
| Fenofibrate | Fenofibrate | 31 | 11 |
| Naproxen | Naproxen | 31 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Topiramate | Topiramate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 25 |
| Glipizide | Glipizide | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Nystatin | Nystatin | 26 | 11 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Linzess | Linaclotide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $66.82 · 3 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, PREVNAR 20, SHINGRIX, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error